Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Roswitha Gropp

Roswitha Gropp

Hospital of Ludwig-Maximilians-University, Germany

Title: Loss of immunological tolerance as a driving force of infl ammation in the NSG-UC mouse model of ulcerative colitis

Biography

Biography: Roswitha Gropp

Abstract

To date, no comprehensive analysis of autoantibodies in sera of patients with ulcerative colitis has been conducted. To analyse the spectrum of autoantibodies serum-IgG from UC patients and non-UC donors were screened by using a human protein microarray. Screening yielded a remarkable number of 697 diff erentially reactive antigens, most of which are expressed on immune cells suggesting a general lack of tolerance in a subgroup of UC patients. From this analysis, CD99 emerged as a biomarker to discriminate between non-UC and UC patients. In vitro, incubation with CD99 induced the frequencies of CCR4 expressing CD4+ cells (eff ector memory regulatory T cells) and TSLPR expressing CD11b+ macrophages and CD14+ monocytes in peripheral blood mononuclear cells (PBMC), indicating an anti-infl ammatory response. In vivo, challenge with CD99 aggravated disease symptoms and pathological phenotype in NOD-scid IL2Rnull (NSG) mice reconstituted with PBMC from UC donors and challenged with ethanol (NSG-UC) indicating failure to induce tolerance in this mouse model. Treatment with sirolimus, which is known to promote Treg suppressed infl ammation as indicated by decreased clinical and histological scores and IFN mRNA levels and increased frequencies of eff ector memory regulatory T-cells. In contrast, treatment with an anti-CCR4 antibody resulted in depletion of CCR4 expressing CD4+ T-cells and aggravated infl ammation. Th us, autoimmunity seems to be a driving force in the NSG-UC mouse model. Future studies have to show whether this also applies to the human disease and whether shift ing the immunological equilibrium towards tolerance might be a promising therapeutic alternative.